Chemical inhibitors of C6orf141 target various signaling pathways and kinases to achieve inhibition of the protein's function. Staurosporine operates as a broad-spectrum kinase inhibitor, disrupting the phosphorylation events necessary for C6orf141 activity, while rapamycin specifically inhibits the mTOR pathway, which is crucial for the protein's role in cell growth and proliferation. Similarly, LY294002 and Wortmannin both act as PI3K inhibitors, blocking the PI3K-dependent signaling required for C6orf141 activation. These inhibitors, therefore, prevent the propagation of signals that are essential for the protein's activity. PD98059 and U0126, both MEK inhibitors, obstruct the MAPK/ERK pathway, which can be significant for C6orf141's involvement in cell cycle regulation and differentiation signals. SB203580, as a p38 MAP kinase inhibitor, and SP600125, a JNK inhibitor, both impede pathways that could be responsible for the regulatory actions of C6orf141, particularly in response to cellular stress.
Further, inhibitors such as gefitinib and erlotinib, which are EGFR tyrosine kinase inhibitors, block the EGFR signaling pathways, thereby inhibiting the protein's potential involvement in cell proliferation linked signaling cascades. ZM-447439, an Aurora kinase inhibitor, disrupts cell cycle regulation pathways that C6orf141 may be a part of, thus preventing the protein from exerting its effects on cell division. Lastly, Bisindolylmaleimide I functions as a PKC inhibitor, hindering PKC-dependent signaling which could be essential for C6orf141's functional activity. Each chemical inhibitor targets specific aspects of signaling pathways or kinase activities that are vital for the functional expression of C6orf141, thereby effectively inhibiting the protein's activity within the cell. These targeted disruptions collectively contribute to the inhibition of C6orf141, providing a comprehensive approach to impede its function without affecting the overall expression levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum inhibitor of protein kinases. It inhibits C6orf141 by inhibiting the kinases that are necessary for its phosphorylation and subsequent activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. C6orf141 activity is inhibited by rapamycin through the inhibition of mTOR signaling pathways that are essential for C6orf141's function in cell growth and proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. It inhibits C6orf141 by blocking PI3K-dependent signaling pathways, preventing the activation of downstream targets that are necessary for C6orf141 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. It inhibits C6orf141 by the same mechanism as LY294002, through the blockade of PI3K signaling required for C6orf141 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. It inhibits C6orf141 by blocking the MAPK/ERK pathway, which could be crucial for the activity of C6orf141, especially if it is involved in cell cycle regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor which inhibits C6orf141 by preventing the activation of the MAPK/ERK pathway, which is important for C6orf141 function related to cell differentiation signals. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. It inhibits C6orf141 by inhibiting the p38 MAPK pathway, which may play a role in stress response functions of C6orf141. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. It inhibits C6orf141 by blocking JNK signaling pathways, which may be necessary for the regulatory actions of C6orf141. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. It inhibits C6orf141 by blocking EGFR signaling pathways that C6orf141 may be involved in, particularly those related to cell proliferation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor that inhibits C6orf141 by inhibiting the EGFR pathway, which is potentially crucial for C6orf141's role in cellular signaling. | ||||||